Discovery and Optimization of 4-Aminopteridin-7(8 H )-one Derivatives as Potent and Selective mTOR Inhibitors with Favorable Pharmacodynamic and Safety Characteristics
Authors:
- 5 February 2026
- journal article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (4) , 4829-4854
Abstract
The mechanistic target of rapamycin (mTOR) is a central regulator of cell growth and a promising cancer therapeutic target. Using structure-guided design, we developed novel 4-aminopteridin-7(8H)-one derivatives as ATP-competitive mTOR inhibitors. The lead compound T133 (51) demonstrated exceptional mTOR inhibition (Ki = 0.17 nM) with high selectivity, effectively suppressing phosphorylation of downstream effectors, such as AKT, S6K1, and 4EBP1. In HGC-27 gastric cancer cells, T133 potently inhibited proliferation and migration while inducing apoptosis, cell cycle arrest, and autophagy. This efficacy extended to NCI-H1299 lung cancer and T-47D breast cancer cells. In the HGC-27 xenograft mouse model, oral administration of T133 exhibited dose-dependent efficacy comparable to clinical-stage inhibitor PF-04691502, while exhibiting significantly reduced hepatotoxicity, nephrotoxicity, and pulmonary toxicity. Moreover, assessments of T133 on cytochrome P450, hERG, and AMES indicate a favorable safety profile. These findings suggest T133 is a promising mTOR inhibitor, warranting further investigation for cancer therapy.Keywords
Funding Information
- Basic and Applied Basic Research Foundation of Guangdong Province (2023B0303000023)
- Basic and Applied Basic Research Foundation of Guangdong Province (2025A1515012895)
- Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences (GIBHBRP23-02)
- Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences (GIBHBRP24-03)
- Chinese Academy of Sciences (XDB1250000)
This publication has 46 references indexed in Scilit:
- Design, synthesis and biological evaluation of novel 1,3,4,9-tetrahydropyrano[3,4-b]indoles as potential treatment of triple negative breast cancer by suppressing PI3K/AKT/mTOR pathwayBioorganic & Medicinal Chemistry, 2022
- A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancerInvestigational New Drugs, 2018
- The PI3K/AKT/mTOR pathway is activated in gastric cancer with potential prognostic and predictive significanceVirchows Archiv, 2014
- Prognostic implication of TSC1 and mTOR expression in gastric carcinomaJournal of Surgical Oncology, 2014
- Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancerInvestigational New Drugs, 2014
- Design and synthesis of a novel pyrrolidinyl pyrido pyrimidinone derivative as a potent inhibitor of PI3Kα and mTORBioorganic & Medicinal Chemistry Letters, 2012
- PI3K and mTOR Signaling Pathways in Cancer: New Data on Targeted TherapiesCurrent Oncology Reports, 2012
- Imidazo[1,5-a]pyrazines: Orally efficacious inhibitors of mTORC1 and mTORC2Bioorganic & Medicinal Chemistry Letters, 2011
- Prognostic role of p‐mTOR expression in cancer tissues and metastatic lymph nodes in pT2b gastric cancerInternational Journal of Cancer, 2010
- Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental modelInternational Journal of Cancer, 2007